These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 12383943)

  • 21. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzymatic dopamine peroxidation in substantia nigra of human brain.
    Galzigna L; De Iuliis A; Zanatta L
    Clin Chim Acta; 2000 Oct; 300(1-2):131-8. PubMed ID: 10958869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.
    Sitte HH; Pifl C; Rajput AH; Hörtnagl H; Tong J; Lloyd GK; Kish SJ; Hornykiewicz O
    Eur J Neurosci; 2017 Jan; 45(1):192-197. PubMed ID: 27741357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the mesocortical dopaminergic system involved in Parkinson disease?
    Javoy-Agid F; Agid Y
    Neurology; 1980 Dec; 30(12):1326-30. PubMed ID: 6109265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
    Villares J; Faucheux B; Herrero MT; Obeso JA; Duyckaerts C; Hauw JJ; Agid Y; Hirsch EC
    Exp Neurol; 1998 Nov; 154(1):146-56. PubMed ID: 9875276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
    Cohen G
    J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 29. Oxidation of proteinaceous cysteine residues by dopamine-derived H2O2 in PC12 cells.
    Kim JR; Kwon KS; Yoon HW; Lee SR; Rhee SG
    Arch Biochem Biophys; 2002 Jan; 397(2):414-23. PubMed ID: 11795902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.
    Burbulla LF; Song P; Mazzulli JR; Zampese E; Wong YC; Jeon S; Santos DP; Blanz J; Obermaier CD; Strojny C; Savas JN; Kiskinis E; Zhuang X; Krüger R; Surmeier DJ; Krainc D
    Science; 2017 Sep; 357(6357):1255-1261. PubMed ID: 28882997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in SK channel expression in the basal ganglia after partial nigrostriatal dopamine lesions in rats: Functional consequences.
    Mourre C; Manrique C; Camon J; Aidi-Knani S; Deltheil T; Turle-Lorenzo N; Guiraudie-Capraz G; Amalric M
    Neuropharmacology; 2017 Feb; 113(Pt A):519-532. PubMed ID: 27825825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electro-acupuncture stimulation acts on the basal ganglia output pathway to ameliorate motor impairment in Parkinsonian model rats.
    Jia J; Li B; Sun ZL; Yu F; Wang X; Wang XM
    Behav Neurosci; 2010 Apr; 124(2):305-10. PubMed ID: 20364891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease.
    Bezard E; Crossman AR; Gross CE; Brotchie JM
    FASEB J; 2001 Apr; 15(6):1092-4. PubMed ID: 11292678
    [No Abstract]   [Full Text] [Related]  

  • 34. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
    Jana S; Maiti AK; Bagh MB; Banerjee K; Das A; Roy A; Chakrabarti S
    Brain Res; 2007 Mar; 1139():195-200. PubMed ID: 17291463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.
    Jellinger K; Linert L; Kienzl E; Herlinger E; Youdim MB
    J Neural Transm Suppl; 1995; 46():297-314. PubMed ID: 8821067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polychlorinated biphenyl-induced neurotoxicity in organotypic cocultures of developing rat ventral mesencephalon and striatum.
    Lyng GD; Snyder-Keller A; Seegal RF
    Toxicol Sci; 2007 May; 97(1):128-39. PubMed ID: 17324953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism.
    Frank MJ
    J Cogn Neurosci; 2005 Jan; 17(1):51-72. PubMed ID: 15701239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization.
    German DC; Manaye K; Smith WK; Woodward DJ; Saper CB
    Ann Neurol; 1989 Oct; 26(4):507-14. PubMed ID: 2817827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.